Turnstone Biologics Corporation (TSBX) Actualités

Form 8-K - Current report

Turnstone Biologics Announces Plans to Explore Strategic Alternatives

SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent...

Form 8-K - Current report

Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a...

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable...

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]